RevOpsis Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Investors
-
2
RevOpsis Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to develop innovative treatments for chronic diseases, particularly in ophthalmology. The company's therapy aims at treating retinal diseases like age-related macular degeneration (AMD) by targeting angiogenic factors involved in disease progression using a plug-and-play system to accelerate the design and development of multispecific biologics, enabling doctors to improve the quality of life for patients.
Contact Information
Website
www.revopsis.comCorporate Office
- 4109 Chandlerwood
- Springfield, IL 62711
- United States
Corporate Office
- 4109 Chandlerwood
- Springfield, IL 62711
- United States
RevOpsis Therapeutics Timeline
RevOpsis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 17-Sep-2025 | Completed | Generating Revenue | |||
| 3. Grant | 15-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC | 25-Apr-2024 | $16.5M | $16.6M | Completed | Pre-Clinical Trials | |
| 1. Later Stage VC | 24-Aug-2022 | $100K | $100K | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
RevOpsis Therapeutics Patents
RevOpsis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260308242-A1 | Compostions of multispecific antigen binding polypeptides and methods of use | Pending | 26-Mar-2025 | ||
| WO-2026207091-A1 | Compostions of multispecific antigen binding polypeptides and methods of use | Pending | 26-Mar-2025 | ||
| AU-2024354938-A1 | Compostions of multispecific antigen binding polypeptides and methods of use | Pending | 03-Oct-2023 | ||
| EP-4788700-A1 | Compostions of multispecific antigen binding polypeptides and methods of use | Pending | 03-Oct-2023 | ||
| WO-2025076131-A1 | Compostions of multispecific antigen binding polypeptides and methods of use | Inactive | 03-Oct-2023 | C07K16/22 |
RevOpsis Therapeutics Signals
RevOpsis Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ExSight Ventures | Venture Capital | Minority | ||
| National Institutes of Health | Government |
RevOpsis Therapeutics FAQs
-
When was RevOpsis Therapeutics founded?
RevOpsis Therapeutics was founded in 2018.
-
Where is RevOpsis Therapeutics headquartered?
RevOpsis Therapeutics is headquartered in Springfield, IL.
-
What is the size of RevOpsis Therapeutics?
RevOpsis Therapeutics has 4 total employees.
-
What industry is RevOpsis Therapeutics in?
RevOpsis Therapeutics’s primary industry is Drug Discovery.
-
Is RevOpsis Therapeutics a private or public company?
RevOpsis Therapeutics is a Private company.
-
What is RevOpsis Therapeutics’s current revenue?
The current revenue for RevOpsis Therapeutics is .
-
How much funding has RevOpsis Therapeutics raised over time?
RevOpsis Therapeutics has raised $16.6M.
-
Who are RevOpsis Therapeutics’s investors?
ExSight Ventures and National Institutes of Health have invested in RevOpsis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process